Literature DB >> 36112222

TREM2 risk variants are associated with atypical Alzheimer's disease.

Boram Kim1, EunRan Suh2, Aivi T Nguyen1, Stefan Prokop3, Bailey Mikytuck1, Olamide A Olatunji1, John L Robinson2, Murray Grossman4, Jeffrey S Phillips4, David J Irwin4, Dawn Mechanic-Hamilton5, David A Wolk5, John Q Trojanowski2, Corey T McMillan4, Vivianna M Van Deerlin2, Edward B Lee6.   

Abstract

Alzheimer's disease (AD) has multiple clinically and pathologically defined subtypes where the underlying causes of such heterogeneity are not well established. Rare TREM2 variants confer significantly increased risk for clinical AD in addition to other neurodegenerative disease clinical phenotypes. Whether TREM2 variants are associated with atypical clinical or pathologically defined subtypes of AD is not known. We studied here the clinical and pathological features associated with TREM2 risk variants in an autopsy-confirmed cohort. TREM2 variant cases were more frequently associated with non-amnestic clinical syndromes. Pathologically, TREM2 variant cases were associated with an atypical distribution of neurofibrillary tangle density with significantly lower hippocampal NFT burden relative to neocortical NFT accumulation. In addition, NFT density but not amyloid burden was associated with an increase of dystrophic microglia. TREM2 variant cases were not associated with an increased prevalence, extent, or severity of co-pathologies. These clinicopathological features suggest that TREM2 variants contribute to clinical and pathologic AD heterogeneity by altering the distribution of neurofibrillary degeneration and tau-dependent microglial dystrophy, resulting in hippocampal-sparing and non-amnestic AD phenotypes.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Behavioral variant; Comorbidity; Dementia; Primary progressive aphasia; TREM2; Tau

Year:  2022        PMID: 36112222     DOI: 10.1007/s00401-022-02495-4

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   15.887


  53 in total

1.  18F-flortaucipir uptake patterns in clinical subtypes of primary progressive aphasia.

Authors:  Hanna Cho; Hee Jin Kim; Jae Yong Choi; Young Hoon Ryu; Myung Sik Lee; Duk L Na; Sang Won Seo; Chul Hyoung Lyoo
Journal:  Neurobiol Aging       Date:  2018-11-23       Impact factor: 4.673

2.  Stages of pTDP-43 pathology in amyotrophic lateral sclerosis.

Authors:  Johannes Brettschneider; Kelly Del Tredici; Jon B Toledo; John L Robinson; David J Irwin; Murray Grossman; EunRan Suh; Vivianna M Van Deerlin; Elisabeth M Wood; Young Baek; Linda Kwong; Edward B Lee; Lauren Elman; Leo McCluskey; Lubin Fang; Simone Feldengut; Albert C Ludolph; Virginia M-Y Lee; Heiko Braak; John Q Trojanowski
Journal:  Ann Neurol       Date:  2013-06-19       Impact factor: 10.422

3.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

Authors:  Bruno Dubois; Howard H Feldman; Claudia Jacova; Harald Hampel; José Luis Molinuevo; Kaj Blennow; Steven T DeKosky; Serge Gauthier; Dennis Selkoe; Randall Bateman; Stefano Cappa; Sebastian Crutch; Sebastiaan Engelborghs; Giovanni B Frisoni; Nick C Fox; Douglas Galasko; Marie-Odile Habert; Gregory A Jicha; Agneta Nordberg; Florence Pasquier; Gil Rabinovici; Philippe Robert; Christopher Rowe; Stephen Salloway; Marie Sarazin; Stéphane Epelbaum; Leonardo C de Souza; Bruno Vellas; Pieter J Visser; Lon Schneider; Yaakov Stern; Philip Scheltens; Jeffrey L Cummings
Journal:  Lancet Neurol       Date:  2014-06       Impact factor: 44.182

Review 4.  The Physiology, Pathology, and Potential Therapeutic Applications of the TREM2 Signaling Pathway.

Authors:  Aleksandra Deczkowska; Assaf Weiner; Ido Amit
Journal:  Cell       Date:  2020-06-11       Impact factor: 41.582

Review 5.  Staging of Alzheimer's disease-related neurofibrillary changes.

Authors:  H Braak; E Braak
Journal:  Neurobiol Aging       Date:  1995 May-Jun       Impact factor: 4.673

6.  Criteria for the diagnosis of corticobasal degeneration.

Authors:  Melissa J Armstrong; Irene Litvan; Anthony E Lang; Thomas H Bak; Kailash P Bhatia; Barbara Borroni; Adam L Boxer; Dennis W Dickson; Murray Grossman; Mark Hallett; Keith A Josephs; Andrew Kertesz; Suzee E Lee; Bruce L Miller; Stephen G Reich; David E Riley; Eduardo Tolosa; Alexander I Tröster; Marie Vidailhet; William J Weiner
Journal:  Neurology       Date:  2013-01-29       Impact factor: 9.910

Review 7.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

8.  TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis.

Authors:  Janet Cady; Erica D Koval; Bruno A Benitez; Craig Zaidman; Jennifer Jockel-Balsarotti; Peggy Allred; Robert H Baloh; John Ravits; Ericka Simpson; Stanley H Appel; Alan Pestronk; Alison M Goate; Timothy M Miller; Carlos Cruchaga; Matthew B Harms
Journal:  JAMA Neurol       Date:  2014-04       Impact factor: 18.302

9.  Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies.

Authors:  Iris Broce; Celeste M Karch; Natalie Wen; Chun C Fan; Yunpeng Wang; Chin Hong Tan; Naomi Kouri; Owen A Ross; Günter U Höglinger; Ulrich Muller; John Hardy; Parastoo Momeni; Christopher P Hess; William P Dillon; Zachary A Miller; Luke W Bonham; Gil D Rabinovici; Howard J Rosen; Gerard D Schellenberg; Andre Franke; Tom H Karlsen; Jan H Veldink; Raffaele Ferrari; Jennifer S Yokoyama; Bruce L Miller; Ole A Andreassen; Anders M Dale; Rahul S Desikan; Leo P Sugrue
Journal:  PLoS Med       Date:  2018-01-09       Impact factor: 11.069

10.  Consensus classification of posterior cortical atrophy.

Authors:  Sebastian J Crutch; Jonathan M Schott; Gil D Rabinovici; Melissa Murray; Julie S Snowden; Wiesje M van der Flier; Bradford C Dickerson; Rik Vandenberghe; Samrah Ahmed; Thomas H Bak; Bradley F Boeve; Christopher Butler; Stefano F Cappa; Mathieu Ceccaldi; Leonardo Cruz de Souza; Bruno Dubois; Olivier Felician; Douglas Galasko; Jonathan Graff-Radford; Neill R Graff-Radford; Patrick R Hof; Pierre Krolak-Salmon; Manja Lehmann; Eloi Magnin; Mario F Mendez; Peter J Nestor; Chiadi U Onyike; Victoria S Pelak; Yolande Pijnenburg; Silvia Primativo; Martin N Rossor; Natalie S Ryan; Philip Scheltens; Timothy J Shakespeare; Aida Suárez González; David F Tang-Wai; Keir X X Yong; Maria Carrillo; Nick C Fox
Journal:  Alzheimers Dement       Date:  2017-03-02       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.